Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

Higher disease activity is linked to faster eGFR decline and a greater risk for significant kidney dysfunction in RA.

Why is the treatment of chronic and rare diseases so difficult in today’s world? A long list of possible medications and ...

The FTC last month sued the big PBMs over their practices in this arena, saying that they forced up insulin list ... part of ...

Autoimmune illnesses occur when your body’s defences, collectively referred to as the immune system, are overactive and end ...

Persistent pain is common in rheumatoid arthritis. But patient-reported outcomes tools can help clinicians determine a care plan.

While pharmacy benefits managers have been touted for their ability to save costs, their operations may actually contribute ...

Alright, buckle up, shoppers! Amazon is a jungle out there, but we've hacked our way through the vines of viral TikTok ...

Mean girls, bad breath, and cyberbullying top WebMD's pictorial guide to tricky situations faced by teen girls. Health experts explain when and how to get help. See these signs of puberty for ...

External Affairs Minister Dr S Jaishankar arrived in Islamabad on Tuesday to attend the SCO Summit being hosted by Pakistan.